AC Immune SA IMR.F Stock
AC Immune SA Price Chart
AC Immune SA IMR.F Financial and Trading Overview
AC Immune SA stock price | 3.74 EUR |
Previous Close | 1.86 EUR |
Open | 1.76 EUR |
Bid | 1.77 EUR x 0 |
Ask | 1.81 EUR x 0 |
Day's Range | 1.76 - 1.76 EUR |
52 Week Range | 1.57 - 3.64 EUR |
Volume | 3.48K EUR |
Avg. Volume | 2.31K EUR |
Market Cap | 147M EUR |
Beta (5Y Monthly) | 0.574647 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.64 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.2 EUR |
IMR.F Valuation Measures
Enterprise Value | 52.61M EUR |
Trailing P/E | N/A |
Forward P/E | 19.533333 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 37.35824 |
Price/Book (mrq) | 0.961181 |
Enterprise Value/Revenue | 13.369 |
Enterprise Value/EBITDA | -0.776 |
Trading Information
AC Immune SA Stock Price History
Beta (5Y Monthly) | 0.574647 |
52-Week Change | -18.33% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.64 EUR |
52 Week Low | 1.57 EUR |
50-Day Moving Average | 1.97 EUR |
200-Day Moving Average | 2.3 EUR |
IMR.F Share Statistics
Avg. Volume (3 month) | 2.31K EUR |
Avg. Daily Volume (10-Days) | 1.51K EUR |
Shares Outstanding | 83.62M |
Float | 32.87M |
Short Ratio | N/A |
% Held by Insiders | 53.87% |
% Held by Institutions | 18.13% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1768.43% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -21.49% |
Return on Equity (ttm) | -37.82% |
Income Statement
Revenue (ttm) | 3.94M EUR |
Revenue Per Share (ttm) | 0.05 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -56401000 EUR |
EBITDA | -67819000 EUR |
Net Income Avi to Common (ttm) | -69418000 EUR |
Diluted EPS (ttm) | -0.74 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 105.43M EUR |
Total Cash Per Share (mrq) | 1.26 EUR |
Total Debt (mrq) | 2.67M EUR |
Total Debt/Equity (mrq) | 1.74 EUR |
Current Ratio (mrq) | 10.385 |
Book Value Per Share (mrq) | 1.829 |
Cash Flow Statement
Operating Cash Flow (ttm) | -67226000 EUR |
Levered Free Cash Flow (ttm) | -42600752 EUR |
Profile of AC Immune SA
Country | Germany |
State | N/A |
City | Lausanne |
Address | Building B |
ZIP | 1015 |
Phone | 41 21 345 91 21 |
Website | https://www.acimmune.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 126 |
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Q&A For AC Immune SA Stock
What is a current IMR.F stock price?
AC Immune SA IMR.F stock price today per share is 3.74 EUR.
How to purchase AC Immune SA stock?
You can buy IMR.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AC Immune SA?
The stock symbol or ticker of AC Immune SA is IMR.F.
Which industry does the AC Immune SA company belong to?
The AC Immune SA industry is Biotechnology.
How many shares does AC Immune SA have in circulation?
The max supply of AC Immune SA shares is 99.67M.
What is AC Immune SA Price to Earnings Ratio (PE Ratio)?
AC Immune SA PE Ratio is now.
What was AC Immune SA earnings per share over the trailing 12 months (TTM)?
AC Immune SA EPS is -0.64 EUR over the trailing 12 months.
Which sector does the AC Immune SA company belong to?
The AC Immune SA sector is Healthcare.